World's Best Scientists 2026 revealed!
Margaret A. Shipp

Margaret A. Shipp

D-Index & Metrics

Medicine

D-Index
103
Citations
60043
World Ranking
7185
National Ranking
3769

Research.com Recognitions

  • 2014 - Member of the National Academy of Medicine (NAM)
  • Member of the Association of American Physicians
  • Member of the Association of American Physicians

Overview

Margaret A. Shipp is affiliated with Harvard University in the United States. Their research primarily focuses on Medicine, with significant contributions within Oncology, Pathology and Forensic Medicine, Molecular Biology, Immunology, and Neurology.

The main topics of their work include:

  • Lymphoma Diagnosis and Treatment
  • Cancer Immunotherapy and Biomarkers
  • CAR-T cell therapy research
  • CNS Lymphoma Diagnosis and Treatment
  • Immune Cell Function and Interaction
  • Chronic Lymphocytic Leukemia Research
  • Cancer Genomics and Diagnostics

Margaret A. Shipp has contributed to a number of recent papers, highlighting developments in lymphoma and immunotherapy. Selected recent publications include:

  • The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee (2022, Blood)
  • A peripheral immune signature of responsiveness to PD-1 blockade in patients with classical Hodgkin lymphoma (2020, Nature Medicine)
  • Nivolumab+AVD in Advanced-Stage Classic Hodgkin's Lymphoma (2024, New England Journal of Medicine)
  • Five-year follow-up of KEYNOTE-087: pembrolizumab monotherapy for relapsed/refractory classical Hodgkin lymphoma (2023, Blood)
  • Nivolumab for relapsed/refractory classical Hodgkin lymphoma: 5-year survival from the pivotal phase 2 CheckMate 205 study (2023, Blood Advances)

The most frequent co-authors collaborating with Margaret A. Shipp include:

  • Scott J. Rodig (23 joint publications)
  • Philippe Armand (19 joint publications)
  • Robert Redd (13 joint publications)
  • Vignesh Shanmugam (13 joint publications)
  • Pier Luigi Zinzani (11 joint publications)

Publications by Margaret A. Shipp appear repeatedly in key scientific journals such as:

  • Blood (19 publications)
  • Hematological Oncology (6 publications)
  • Blood Advances (5 publications)
  • ONCOLOGY (5 publications)
  • bioRxiv (Cold Spring Harbor Laboratory) (5 publications)

The scientist has been recognized with memberships in professional organizations, including being named a Member of the National Academy of Medicine in 2014 and a Member of the Association of American Physicians.

Best Publications

  • A predictive model for aggressive non-Hodgkin's lymphoma

    M. A. Shipp;D. P. Harrington;J. R. Anderson;J. O. Armitage

  • Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas

    B D Cheson;S J Horning;B Coiffier;M A Shipp

  • PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma

    Stephen M. Ansell;Alexander M. Lesokhin;Alexander M. Lesokhin;Ivan Borrello;Ahmad Halwani

  • Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning

    Margaret A. Shipp;Ken N. Ross;Pablo Tamayo;Andrew P. Weng

  • Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes

    Bjoern Chapuy;Chip Stewart;Andrew J Dunford;Jaegil Kim

  • Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma

    Michael R. Green;Stefano Monti;Scott J. Rodig;Przemyslaw Juszczynski

  • Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing

    Jens G. Lohr;Petar Stojanov;Petar Stojanov;Michael S. Lawrence;Daniel Auclair

  • Nivolumab in patients with relapsed or refractory hematologic malignancy: Preliminary results of a phase ib study

    Alexander M. Lesokhin;Alexander M. Lesokhin;Stephen M. Ansell;Philippe Armand;Emma C. Scott

  • The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma

    Kerry J. Savage;Stefano Monti;Jeffery L. Kutok;Giorgio Cattoretti

  • Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma.

    Robert Chen;Pier Luigi Zinzani;Michelle A. Fanale;Philippe Armand

  • Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial

    Anas Younes;Armando Santoro;Margaret Shipp;Pier Luigi Zinzani

  • Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response

    Stefano Monti;Kerry J. Savage;Jeffery L. Kutok;Friedrich Feuerhake

  • Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia

    Jonathan W. Friedberg;Jeff Sharman;John Sweetenham;Patrick B. Johnston

  • PD-L1 EXPRESSION IS CHARACTERISTIC OF A SUBSET OF AGGRESSIVE B-CELL LYMPHOMAS AND VIRUS-ASSOCIATED MALIGNANCIES

    Benjamin J. Chen;Bjoern Chapuy;Jing Ouyang;Heather H. Sun

  • Discovery and Characterization of Super-Enhancer-Associated Dependencies in Diffuse Large B Cell Lymphoma

    Bjoern Chapuy;Michael R. McKeown;Charles Y. Lin;Stefano Monti

  • Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial.

    Philippe Armand;Andreas Engert;Anas Younes;Michelle A Fanale

  • PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome

    Margaretha G.M. Roemer;Ranjana H. Advani;Azra H. Ligon;Yasodha Natkunam

  • Report on a workshop convened to discuss the pathological and staging classifications of gastrointestinal tract lymphoma

    A Rohatiner;F d'Amore;B Coiffier;D Crowther

  • Constitutive AP-1 Activity and EBV Infection Induce PD-L1 in Hodgkin Lymphomas and Posttransplant Lymphoproliferative Disorders: Implications for Targeted Therapy

    Michael R Green;Scott J. Rodig;Przemyslaw Juszczynski;Jing Ouyang

  • Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure

    Philippe Armand;Margaret A. Shipp;Vincent Ribrag;Jean Marie Michot

Frequent Co-Authors

Scott J. Rodig
Scott J. Rodig Harvard University
Philippe Armand
Philippe Armand Harvard University
Donna Neuberg
Donna Neuberg Harvard University
Jeffery L. Kutok
Jeffery L. Kutok Epizyme (United States)
Todd R. Golub
Todd R. Golub Harvard University
Pier Luigi Zinzani
Pier Luigi Zinzani University of Bologna
Gad Getz
Gad Getz Broad Institute
Geraldine S. Pinkus
Geraldine S. Pinkus Brigham and Women's Hospital
Kerry J. Savage
Kerry J. Savage University of British Columbia
Jon C. Aster
Jon C. Aster Harvard Medical School

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re considering a career in medicine but prefer flexibility, several online options can help you advance quickly and affordably. For registered nurses looking to earn a bachelor’s degree without breaking the bank, the cheapest rn to bsn program options offer a pathway to increased job opportunities and higher salaries.

Those without a nursing background who want to enter the field at the master’s level can explore direct entry msn programs online. These programs allow non-nurses to fast-track their education and quickly gain essential qualifications.

If admission barriers concern you, finding the easiest bsn program to get into can simplify your journey—letting you start your nursing career sooner.

For those interested in supporting the healthcare system without direct patient care, consider an online medical billing and coding with financial aid program. These flexible courses are ideal for launching a medical office career, often with financial support available.

Best Scientists Citing Margaret A. Shipp

Trending Scientists